Figueroa-Campos, A.; Sánchez-Dengra, B.; Merino, V.; Dahan, A.; González-Álvarez, I.; García-Arieta, A.; González-Álvarez, M.; Bermejo, M.
Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool. Pharmaceutics 2020, 12, 633.
https://doi.org/10.3390/pharmaceutics12070633
AMA Style
Figueroa-Campos A, Sánchez-Dengra B, Merino V, Dahan A, González-Álvarez I, García-Arieta A, González-Álvarez M, Bermejo M.
Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool. Pharmaceutics. 2020; 12(7):633.
https://doi.org/10.3390/pharmaceutics12070633
Chicago/Turabian Style
Figueroa-Campos, Andrés, Bárbara Sánchez-Dengra, Virginia Merino, Arik Dahan, Isabel González-Álvarez, Alfredo García-Arieta, Marta González-Álvarez, and Marival Bermejo.
2020. "Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool" Pharmaceutics 12, no. 7: 633.
https://doi.org/10.3390/pharmaceutics12070633
APA Style
Figueroa-Campos, A., Sánchez-Dengra, B., Merino, V., Dahan, A., González-Álvarez, I., García-Arieta, A., González-Álvarez, M., & Bermejo, M.
(2020). Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool. Pharmaceutics, 12(7), 633.
https://doi.org/10.3390/pharmaceutics12070633